• Profile
Close

Activity and safety of cetuximab plus modified FOLFOXIRI followed by maintenance with cetuximab or bevacizumab for RAS and BRAF wild-type metastatic colorectal cancer: A randomized phase 2 clinical trial

JAMA Oncology Feb 23, 2018

Cremolini C, et al. - The activity and safety of cetuximab plus modified FOLFOXIRI (mFOLFOXIRI) were determined along with the role of maintenance cetuximab or bevacizumab in RAS and BRAF wild-type metastatic colorectal cancer (mCRC). The feasibility of a 4-month induction regimen of mFOLFOXIRI plus cetuximab was demonstrated. Moreover, this regimen provided relevant activity results, resulting in a high surgical resection rate.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay